Comparative Study of Biopharmaceutical Innovation Policies: India and the European Union

Abstract

Biopharmaceutical innovation has become a critical determinant of national health security, economic growth, and technological
advancement in the contemporary global order. This paper presents a comprehensive comparative study of biopharmaceutical
innovation policies in India and the European Union (EU), examining how divergent regulatory philosophies and institutional
frameworks shape research and development outcomes. The EU represents a highly integrated and harmonized innovation
ecosystem, characterized by centralized regulatory oversight through the European Medicines Agency, robust intellectual
property protection, and extensive public funding mechanisms such as Horizon Europe. Using a qualitative doctrinal and
comparative policy analysis, this study evaluates regulatory approval processes, intellectual property regimes, innovation
incentives, and market access mechanisms in both jurisdictions. The findings indicate that while the EU’s policy framework
offers greater regulatory certainty and innovation-specific exclusivities, India leverages intellectual property flexibilities and
cost-efficient manufacturing capabilities to foster a competitive biopharmaceutical sector. The paper argues that strategic policy
learning, regulatory cooperation, and calibrated intellectual property governance can bridge existing gaps and enhance
innovation capacity without undermining public health objectives. Ultimately, the study contributes to the discourse on
comparative pharmaceutical governance by highlighting pathways for sustainable and inclusive biopharmaceutical innovation
in both developed and emerging economies.